undamentalytics Newsletter
Sign in

Neuroone Medical Technologies Corp (NMTC) stock

Add to watchlist

Add holding +

NASDAQ: NMTC Nasdaq Health Care Equipment Next results ~December 22, 2026

D Fundamentals grade

Neuroone Medical Technologies Corp is a US-listed company in the health care equipment industry. Its financial year ends in September.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$1.9

Forward price-to-sales vs peers

Base case. Range ~$1.9–$7.1. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Neuroone Medical Technologies Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 1 selling2 purchases and 6 sales by directors and officers, last 12 monthsInsider trades
  • Funds23 adding, 1 cuttingOf 2 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Neuroone Medical Technologies files

Where Neuroone Medical Technologies stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $9m, up 42.8% on a year earlier, slower than the 59.6% growth a quarter earlier. That growth ranks 13 of 103 among the health care equipment companies we cover. Free-cash-flow margin fell to -75.6% from -61.6% a year earlier. Operating margin widened to -83.4% from -85.6%. The diluted share count is up 41.1% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $1.06 a share, against a share price of $1.00.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~December 22, 2026 (estimated)

Neuroone Medical Technologies Corp's trailing-twelve-month revenue grew 42.8% year on year, with a free-cash-flow margin of -75.6%. Where it stands out: revenue growth of 42.8% ranks 17 of 129 health care equipment companies we cover. Where it lags: change in growth rate of -16.8pp ranks 115 of 129 health care equipment companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 75.2% while net income fell 39.5%: a 36pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 42.8% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Growth slowing. The growth rate is 16.8 points lower than a quarter earlier.
  • Loss-making. Operating margin is -83.4%: costs exceed revenue.
  • Burning cash. Free cash flow was -75.6% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 41.1% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 84% and a beta of 0.8 against the S&P 500.

Latest results: FY2026 Q3

Filed August 13, 2026
Earnings per share
-$0.28 against an average estimate of -$0.22: missed by 29.2%
Revenue
$2m, up 16.3% on a year earlier
Share reaction
+0.9% in the first session after the results on October 5, 2026, against +1.2% for the S&P 500
Next report
August 13, 2026

Neuroone Medical Technologies' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.9%
  • 1 week+16.3%
  • 1 month-16.5%
  • This year-79.4%
  • 1 year-80.3%
  • 5 years-94.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$9.5M
Operating margin
-83.4%
Net margin
-78.6%
EPS (TTM, diluted)
$-1.27

Growth

Revenue growth
+42.8%
Change in growth rate
−16.8 pts
Share count change
+41.1%

Cash

Free cash flow (TTM)
-$7.2M
FCF margin
-75.6%
Stock pay % of revenue
14.9%

Earnings

Last results
October 5, 2026
Next results (est.)
December 22, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Announcement
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Neuroone Medical Technologies Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Neuroone Medical Technologies Corp as an operating company, with every model that fits that kind of business. Cost of equity 10.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.28 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: the projected cash flows don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.9 ~$2.1–$7.1 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.9 ~$1.9–$7.1 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Neuroone Medical Technologies Corp with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025
Share price$23.70$10.14$5.34$5.94$5.33
Market value$254m$162m$97m$159m$214m
+ Net debt (− = net cash)−$7m−$8m−$5m−$1m−$7m
Enterprise value$247m$154m$92m$158m$208m
Multiples
Price / sales n/mn/m49.6x46.0x23.5x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

21 /100

Weak moat

How hard Neuroone Medical Technologies's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -175.4% of total assets over 9 years.

  • Pricing power 11 / 20

    Gross margin has been a median 55.6%, moving by 47.7 percentage points (standard deviation) across 7 years.

  • Durability 10 / 20

    Operating margin has been a median -1402.8%; its worst year was -28241.6%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -290.3% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 1234.3% over five years; stock-based pay has been a median 32.5% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.71 −32% $11m +16%
Next −$0.63 +11% $13m +27%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −15.1% on 90 days ago. In the last 30 days, 1 analyst raised Neuroone Medical Technologies Corp's forecast and 0 cut it.

Consensus EPS forecast Neuroone Medical Technologies Corp, last 90 days
−$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.84 Current fiscal year, 60 days ago: −$0.84 Current fiscal year, 30 days ago: −$0.74 Current fiscal year, 7 days ago: −$0.74 Current fiscal year, Now: −$0.71 −$0.71 Next fiscal year, 90 days ago: −$0.51 Next fiscal year, 60 days ago: −$0.51 Next fiscal year, 30 days ago: −$0.63 Next fiscal year, 7 days ago: −$0.63 Next fiscal year, Now: −$0.63 −$0.63

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.84−$0.51
60 days ago −$0.84−$0.51
30 days ago −$0.74−$0.63
7 days ago −$0.74−$0.63
Now −$0.71−$0.63

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.22 −$0.28 −29.2%
Dec 2025 −$0.24 −$0.18 +25.0%
Sept 2025 −$0.24 −$0.24 0.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026123
  2. Sep 2026123

Counts of recommendations published by analysts covering Neuroone Medical Technologies Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.4%
of tradable shares
Days to cover
1.17
at average volume
Short interest, 1 month
+174%
to October 15, 2026
Held by institutions
22%
of shares
Held by insiders
25.4%
of shares
Employees
18
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −80.3%

$4.75 on October 31, 2025 to $0.94

ThenNowEffect
Revenue (last 12 months) $7m $9m +42.8%
P/S multiple 4.2x 0.8x −80.2%
Share count 6m 8m −30.6%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
NMTC−59%−38%+32%−48%−8%−79%
Industry peers (median)−7%−37%−9%−19%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
NMTC33%50%50%25%42%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
NMTC−83%−82%−59%−64%−65%−86%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since March 15, 2018: 100% from February 25, 2019 to October 26, 2026. Getting back needed a 20027% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.80 – $5.89
From 52-week high
−84.1%
vs 50-day average
−28.1%
vs 200-day average
−70.6%
Volatility (1 year)
84%
Beta vs S&P 500
0.76

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±7.2%
After a week
5 up, 7 down
typical move ±8.3%
After a month
5 up, 6 down
typical move ±13.1%
Results releasedNext dayS&P 500 next day5 days21 days
October 5, 2026 +0.9% +1.2% −4.0% —
August 13, 2026 +27.6% +0.5% +41.4% −1.3%
May 12, 2026 +4.2% +0.4% −5.1% −25.2%
February 17, 2026 −16.4% +0.7% −14.3% −9.0%
December 17, 2025 +1.3% −0.4% +8.3% +27.3%
October 6, 2025 +14.0% 0.0% −3.2% −22.3%
August 14, 2025 −4.7% −0.2% −10.6% +2.3%
May 13, 2025 +5.9% +0.8% −0.2% −7.9%
February 12, 2025 +4.6% +0.7% +2.8% −0.9%
January 10, 2025 +3.7% −1.4% −2.8% +0.9%
December 17, 2024 −2.2% −3.4% +1.7% +34.7%
August 14, 2024 −1.4% +2.0% +5.0% +12.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Neuroone Medical Technologies Corp in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Neuroone Medical Technologies Corp
$0 $5M $10M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $2M Revenue (TTM), FY24 Q1: $2.8M Revenue (TTM), FY24 Q2: $3.7M Revenue (TTM), FY24 Q3: $3.9M Revenue (TTM), FY24 Q4: $3.5M Revenue (TTM), FY25 Q1: $5.7M Revenue (TTM), FY25 Q2: $5.8M Revenue (TTM), FY25 Q3: $6.6M Revenue (TTM), FY25 Q4: $9.1M Revenue (TTM), FY26 Q1: $8.7M Revenue (TTM), FY26 Q2: $9.2M Revenue (TTM), FY26 Q3: $9.5M $9.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $2M
FY24 Q1 $2.8M
FY24 Q2 $3.7M
FY24 Q3 $3.9M
FY24 Q4 $3.5M
FY25 Q1 $5.7M
FY25 Q2 $5.8M
FY25 Q3 $6.6M
FY25 Q4 $9.1M
FY26 Q1 $8.7M
FY26 Q2 $9.2M
FY26 Q3 $9.5M
Revenue growth, TTM YoY Neuroone Medical Technologies Corp
0% 500% 1000% 1500% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 1040.7% Revenue growth, TTM YoY, FY24 Q1: 1017.3% Revenue growth, TTM YoY, FY24 Q2: 446.8% Revenue growth, TTM YoY, FY24 Q3: 206.6% Revenue growth, TTM YoY, FY24 Q4: 76.9% Revenue growth, TTM YoY, FY25 Q1: 104.2% Revenue growth, TTM YoY, FY25 Q2: 54.5% Revenue growth, TTM YoY, FY25 Q3: 69.0% Revenue growth, TTM YoY, FY25 Q4: 163.5% Revenue growth, TTM YoY, FY26 Q1: 51.6% Revenue growth, TTM YoY, FY26 Q2: 59.6% Revenue growth, TTM YoY, FY26 Q3: 42.8% 42.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 1040.7%
FY24 Q1 1017.3%
FY24 Q2 446.8%
FY24 Q3 206.6%
FY24 Q4 76.9%
FY25 Q1 104.2%
FY25 Q2 54.5%
FY25 Q3 69.0%
FY25 Q4 163.5%
FY26 Q1 51.6%
FY26 Q2 59.6%
FY26 Q3 42.8%
Operating margin (TTM) Neuroone Medical Technologies Corp
-800% -600% -400% -200% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -612.3% Operating margin (TTM), FY24 Q1: -481.7% Operating margin (TTM), FY24 Q2: -347.5% Operating margin (TTM), FY24 Q3: -311.9% Operating margin (TTM), FY24 Q4: -344.3% Operating margin (TTM), FY25 Q1: -118.0% Operating margin (TTM), FY25 Q2: -114.3% Operating margin (TTM), FY25 Q3: -85.6% Operating margin (TTM), FY25 Q4: -46.5% Operating margin (TTM), FY26 Q1: -87.7% Operating margin (TTM), FY26 Q2: -80.1% Operating margin (TTM), FY26 Q3: -83.4% -83.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -612.3%
FY24 Q1 -481.7%
FY24 Q2 -347.5%
FY24 Q3 -311.9%
FY24 Q4 -344.3%
FY25 Q1 -118.0%
FY25 Q2 -114.3%
FY25 Q3 -85.6%
FY25 Q4 -46.5%
FY26 Q1 -87.7%
FY26 Q2 -80.1%
FY26 Q3 -83.4%
FCF margin (TTM) Neuroone Medical Technologies Corp
-800% -600% -400% -200% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -679.7% FCF margin (TTM), FY24 Q1: -483.5% FCF margin (TTM), FY24 Q2: -324.5% FCF margin (TTM), FY24 Q3: -290.3% FCF margin (TTM), FY24 Q4: -322.4% FCF margin (TTM), FY25 Q1: -123.5% FCF margin (TTM), FY25 Q2: -86.0% FCF margin (TTM), FY25 Q3: -61.6% FCF margin (TTM), FY25 Q4: -32.1% FCF margin (TTM), FY26 Q1: -71.8% FCF margin (TTM), FY26 Q2: -82.3% FCF margin (TTM), FY26 Q3: -75.6% -75.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -679.7%
FY24 Q1 -483.5%
FY24 Q2 -324.5%
FY24 Q3 -290.3%
FY24 Q4 -322.4%
FY25 Q1 -123.5%
FY25 Q2 -86.0%
FY25 Q3 -61.6%
FY25 Q4 -32.1%
FY26 Q1 -71.8%
FY26 Q2 -82.3%
FY26 Q3 -75.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-KT, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Dec 2010 2012 Dec 2011 2013 Dec 2012 2014 Dec 2013 2015 Dec 2014 2016 Dec 2015 2017 Dec 2016 2021 Sept 2021 2022 Sept 2022 2023 Sept 2023 2024 Sept 2024 2025 Sept 2025 LTM Jun 2026
Income
Revenue 0 0 0 0 0 0 0 0 0 2 3 9 9
Gross profit 0 0 0 0 — — — −0 −0 0 1 5 5
EBITDA — — — — — — — −10 −10 −12 −12 −4 −8
Operating income — — −0 −0 −0 −0 −0 −10 −10 −12 −12 −4 −8
Net income −0 −0 −0 −0 −0 −0 −0 −10 −10 −12 −12 −4 −7
Diluted EPS — −$0.03 $0.00 −$0.03 −$0.03 −$0.03 −$0.03 −$0.93 −$0.63 −$0.65 −$0.46 −$0.09 —
Growth (year on year)
Revenue — +362.6% −82.9% +35.6% −38.1% −100.0% — — −3.9% +>999% +76.9% +163.5% +42.8%
Margins
Gross margin 100.0% 60.4% 100.0% 100.0% — — — −54.9% −41.4% 23.4% 31.3% 56.5% 55.6%
EBITDA margin — — — — — — — <−999% <−999% −602.1% −337.1% −43.6% −81.0%
Operating margin — — <−999% <−999% <−999% — — <−999% <−999% −612.3% −344.3% −46.5% −83.4%
Net margin −517.9% −511.4% <−999% <−999% <−999% — — <−999% <−999% −607.4% −356.7% −39.6% −78.6%
Free-cash-flow margin — — — — — — — <−999% <−999% −679.7% −322.4% −32.1% −75.6%
Cash flow
Cash from operations −0 −0 −0 −0 −0 −0 −0 −9 −8 −13 −11 −3 −7
Capital spending — — — — — — — 0 0 0 0 0 0
Free cash flow — — — — — — — −9 −8 −13 −11 −3 −7
Stock-based pay — — — — — — — 2 1 1 1 1 1
Free cash flow after stock pay — — — — — — — −10 −9 −14 −12 −4 −9
Balance sheet
Cash — — — — — — — 7 8 5 1 7 2
Total debt 0 0 — 0 0 0 0 0 0 0 — 0 0
Net debt (negative = net cash) — — — — — — — −7 −8 −5 −1 −7 −2
Diluted shares 1m 2m 2m 2m 2m 2m 2m 11m 16m 18m 27m 40m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $6m
Short-term assets $6mLonger-term assets $0m
What it owes, and who funded it · $6m
Short-term liabilities $2mLonger-term liabilities $0mShareholders' equity $4m
  • Short-term assets cover short-term liabilities $6m of assets due within a year against $2m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $6m short-term assets against $377,125 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Neuroone Medical Technologies Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+41.1%
year over year
R&D spending
57.0%
of revenue
Sales & admin spending
82.0%
of revenue
Days sales outstanding
42 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated NMTC MLSS WOK NUWE NNNN NSPR Median
Revenue, last 12 months $9m $9m $10m $9m $9m $11m $99m
Revenue growth, last 12 months 42.8% 3.7% −14.4% 8.4% 5.6% 53.4% 9.2%
Revenue growth, 3-year average 94.9% −1.9% — 2.8% — 26.6% 13.5%
Revenue growth, latest quarter 16.3% 22.3% — 14.1% — −0.4% 10.2%
Gross margin 55.6% 70.2% 23.8% 69.7% 87.2% 18.1% 61.2%
Operating margin −83.4% −43.6% — −142.9% 66.7% −494.0% −8.5%
Operating margin, 3-year average −160.3% −66.8% — −138.4% — −501.9% −17.9%
Net margin −78.6% −44.0% −10.9% −125.6% 74.1% −484.1% −12.0%
Cash from operations / revenue −74.5% −6.8% 63.4% −138.3% −77.9% −380.1% −1.9%
Free-cash-flow margin −75.6% −7.0% 49.9% −139.7% — −391.7% −3.9%
Free-cash-flow margin, 3-year average −142.5% −53.1% — −126.7% — −372.4% −7.0%
Stock pay / revenue 14.9% 10.3% — 1.0% — 98.8% 6.1%
Change in share count 41.1% 5.9% 128.1% 5.4% 3.3% 63.5% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 42.8% 9.1% 17 of 129
Change in growth rate Growth -16.8pp -0.6pp 115 of 129
Gross margin Profitability 55.6% 61.9% 77 of 123
Operating margin Profitability -83.4% -8.3% 102 of 132
Net margin Profitability -78.6% -12.0% 99 of 133
Free-cash-flow margin Cash generation -75.6% -3.4% 100 of 128
Stock pay as % of revenue Cash generation 14.9% 6.1% 88 of 123
Change in share count Balance sheet 41.1% 3.3% 101 of 115
Days sales outstanding Balance sheet 42 days 57 days 24 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$6.3M
Institutions reporting
24
Shares held vs prior quarter
▲ 10296635.0%
Positions opened / closed
23 / 0

Top buyers and sellers, Q2 2026: 23 institutions bought and 1 sold ; the biggest buyer was Bleichroeder LP (+667K shares) and the biggest seller Sbi Securities Co., Ltd (−7). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Bleichroeder LP $2M 667K 32.4% New
Vanguard Capital Management LLC $1.1M 353K 17.1% New
Bard Associates Inc $928,502 305K 14.8% New
Perkins Capital Management Inc $743,754 245K 11.9% New
Geode Capital Management, LLC $284,446 94K 4.5% New
Sio Capital Management, LLC $251,612 83K 4.0% New
Renaissance Technologies LLC $215,417 71K 3.4% New
Cambridge Investment Research Advisors, Inc. $174,000 57K 2.8% New
Vanguard Fiduciary Trust Co $149,015 49K 2.4% New
Essex Investment Management Co LLC $132,477 44K 2.1% New
Blackrock, Inc. $76,368 25K 1.2% New
Northern Trust Corp $65,050 21K 1.0% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Neuroone Medical Technologies Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $736,999 2 trades by 1 insider, last 12 months Insider sales History → $54,878 6 trades by 1 insider · 0% under pre-set plans
Net ▲ $682,121 net buying
Insider Date Trade Shares Price Value
Wambeke David J. Chief Business Officer August 27, 2026 Buy 33,333 $2.01 $66,999
Christianson Mark Market Development Director June 30, 2026 Sell 10,000 $3.18 $31,800
Christianson Mark Business Development Director March 30, 2026 Sell 15,363 $0.74 $11,369
Christianson Mark Business Development Director March 13, 2026 Sell 100 $0.80 $80
Christianson Mark Business Development Director March 12, 2026 Sell 817 $0.80 $654
Christianson Mark Business Development Director March 11, 2026 Sell 2,109 $0.80 $1,687
Christianson Mark Business Development Director March 10, 2026 Sell 11,611 $0.80 $9,289
Wambeke David J. Chief Business Officer March 1, 2026 Buy 1,000,000 $0.67 $670,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around December 22, 2026 estimated from the company's past filing pattern, not announced

  • October 5, 2026
  • August 13, 2026
  • May 12, 2026
  • February 17, 2026
  • December 17, 2025
  • October 6, 2025

Recent SEC filings

Data status

When each part of this page on Neuroone Medical Technologies Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Neuroone Medical Technologies Corp in brief

What does Neuroone Medical Technologies Corp do?
Neuroone Medical Technologies Corp is a US-listed company in the health care equipment industry. Its financial year ends in September.
What is Neuroone Medical Technologies Corp's stock ticker?
Neuroone Medical Technologies Corp trades under the ticker NMTC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Neuroone Medical Technologies Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Neuroone Medical Technologies Corp reported revenue of $9.5M, 42.8% higher than a year earlier, according to its SEC filings.
What is Neuroone Medical Technologies Corp's free cash flow?
Neuroone Medical Technologies Corp's free-cash-flow margin is -75.6% of revenue over the trailing twelve months, ranking 100 of the 128 health care equipment companies we cover.
Who are Neuroone Medical Technologies Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Bleichroeder LP, Vanguard Capital Management LLC and Bard Associates Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Neuroone Medical Technologies Corp's market cap?
On September 30, 2025, Neuroone Medical Technologies Corp's market capitalisation was about $214M and net debt of -$6.6M. Market figures come from third-party market data and may be delayed.
Who are Neuroone Medical Technologies Corp's competitors?
In our Health Care Equipment peer group, the companies closest to Neuroone Medical Technologies Corp are Milestone Scientific Inc., Work Medical Technology Group LTD, Nuwellis, Inc., Anbio Biotechnology and Inspiremd, Inc. The side-by-side comparison below sets their revenue, margins and growth against Neuroone Medical Technologies Corp's.
Are insiders buying or selling Neuroone Medical Technologies Corp stock?
Over the last 12 months, Neuroone Medical Technologies Corp's directors and officers reported 2 open-market purchases and 6 sales on Form 4. The insider trading page charts every trade.
When is Neuroone Medical Technologies Corp's next earnings date?
Around December 22, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Neuroone Medical Technologies Corp announces its own schedule.